Meeting
2014 ASCO Annual Meeting
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.
Authors
Yingmiao Liu
Duke University Medical Center, Durham, NC
Yingmiao Liu , Jeffrey Melson Clarke , Mark D. Starr , John C. Brady , Herbert Pang , Christel Rushing , Delia Alvarez , Bonne J. Adams , Charles P. Theuer , Herbert Hurwitz , Andrew B. Nixon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Proteomic and Metabolomic Biomarkers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11020)
DOI
10.1200/jco.2014.32.15_suppl.11020
Abstract #
11020
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
First Author: Yingmiao Liu
Poster
2020 ASCO Virtual Scientific Program
Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer.
First Author: Vadryn Pierre
Poster
2016 Genitourinary Cancers Symposium
Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).
First Author: Tanya B. Dorff
Poster
2011 ASCO Annual Meeting
Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: Preliminary outcome results.
First Author: P. M. Harari